Adaptive Biotechnologies CCO reports major option exercises, sales

Rhea-AI Filing Summary

Adaptive Biotechnologies (ADPT) reported insider transactions by its Chief Commercial Officer, Immune Medicine, Sharon Benzeno. On November 20–21, 2025, she executed multiple stock option exercises and related sales of common stock under a Rule 10b5-1 trading plan adopted on August 18, 2025.

She exercised options covering 133,032, 68,961, 834, 20,834, 49,480, 34,375, 119,809 and 83,145 shares at exercise prices between $3.99 and $12.14 per share, converting them into common stock. She then sold 297,925 shares at a weighted average price of $16.54 and 308,477 shares at a weighted average price of $16.91 in multiple transactions within stated price ranges.

Following these transactions, she directly beneficially owns 296,791 shares of Adaptive Biotechnologies common stock.

Insider Trade Summary

Net Seller: 606,402 shares ($10,144,026)

Net Sell 18 txns

Insider BENZENO SHARON

Role Chief Commercial Ofc Imm Med

Sold 606,402 shs ($10.14M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	834	$0.00	--
Exercise	Stock Option (right to buy)	20,834	$0.00	--
Exercise	Stock Option (right to buy)	49,480	$0.00	--
Exercise	Stock Option (right to buy)	34,375	$0.00	--
Exercise	Stock Option (right to buy)	119,809	$0.00	--
Exercise	Stock Option (right to buy)	83,145	$0.00	--
Exercise	Common Stock	834	$6.27	$5K
Exercise	Common Stock	20,834	$6.55	$136K
Exercise	Common Stock	49,480	$6.55	$324K
Exercise	Common Stock	34,375	$7.27	$250K
Exercise	Common Stock	119,809	$12.14	$1.45M
Exercise	Common Stock	83,145	$3.99	$332K
Sale	Common Stock	308,477	$16.91	$5.22M
Exercise	Stock Option (right to buy)	133,032	$0.00	--
Exercise	Stock Option (right to buy)	68,961	$0.00	--
Exercise	Common Stock	133,032	$8.46	$1.13M
Exercise	Common Stock	68,961	$12.14	$837K
Sale	Common Stock	297,925	$16.54	$4.93M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 297,625 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENZENO SHARON

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Ofc Imm Med

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		M(1)		133,032	A	$8.46	525,755	D
Common Stock	11/20/2025		M(1)		68,961	A	$12.14	594,716	D
Common Stock	11/20/2025		S(1)		297,925	D	$16.54(9)	296,791	D
Common Stock	11/21/2025		M(1)		834	A	$6.27	297,625	D
Common Stock	11/21/2025		M(1)		20,834	A	$6.55	318,459	D
Common Stock	11/21/2025		M(1)		49,480	A	$6.55	367,939	D
Common Stock	11/21/2025		M(1)		34,375	A	$7.27	402,314	D
Common Stock	11/21/2025		M(1)		119,809	A	$12.14	522,123	D
Common Stock	11/21/2025		M(1)		83,145	A	$3.99	605,268	D
Common Stock	11/21/2025		S(1)		308,477	D	$16.91(10)	296,791	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.46	11/20/2025		M(1)			133,032	(2)	03/06/2033	Common Stock	133,032	$0	66,517	D
Stock Option (right to buy)	$12.14	11/20/2025		M(1)			68,961	(3)	03/04/2032	Common Stock	68,961	$0	136,970	D
Stock Option (right to buy)	$6.27	11/21/2025		M(1)			834	(4)	04/25/2027	Common Stock	834	$0	0	D
Stock Option (right to buy)	$6.55	11/21/2025		M(1)			20,834	(5)	02/07/2028	Common Stock	20,834	$0	0	D
Stock Option (right to buy)	$6.55	11/21/2025		M(1)			49,480	(6)	10/01/2028	Common Stock	49,480	$0	0	D
Stock Option (right to buy)	$7.27	11/21/2025		M(1)			34,375	(7)	02/07/2029	Common Stock	34,375	$0	0	D
Stock Option (right to buy)	$12.14	11/21/2025		M(1)			119,809	(3)	03/04/2032	Common Stock	119,809	$0	17,161	D
Stock Option (right to buy)	$3.99	11/21/2025		M(1)			83,145	(8)	03/04/2034	Common Stock	83,145	$0	116,404	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

2. The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

3. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

4. The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

5. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

6. The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

7. The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

8. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

9. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

10. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What type of SEC filing did Adaptive Biotechnologies (ADPT) submit?

Adaptive Biotechnologies submitted a Form 4, which reports changes in the beneficial ownership of its equity securities by an insider officer.

Who is the reporting person in this ADPT Form 4 and what is their role?

The reporting person is Sharon Benzeno, who serves as Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies.

What stock option exercises did the ADPT officer report on November 20–21, 2025?

She exercised stock options covering 133,032, 68,961, 834, 20,834, 49,480, 34,375, 119,809 and 83,145 shares at exercise prices between $3.99 and $12.14 per share.

How many Adaptive Biotechnologies (ADPT) shares were sold and at what prices?

She sold 297,925 shares at a weighted average price of $16.54 and 308,477 shares at a weighted average price of $16.91, each in multiple transactions within disclosed price ranges.

How many ADPT shares does the insider own after these transactions?

After the reported option exercises and sales, she directly beneficially owns 296,791 shares of Adaptive Biotechnologies common stock.

Was a Rule 10b5-1 trading plan used for these ADPT insider transactions?

Yes. The transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

What are the vesting terms disclosed for the ADPT stock options in this Form 4?

The options generally vested as to 1/4 of the shares on a specified initial vesting date (such as March 6, 2024, March 4, 2023, or March 4, 2025), with 1/48 of the shares vesting at the end of each full month of continuous service thereafter until fully vested.